MicroRNA‑29‑3p regulates the β‑catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells

Xia,Jie; Li,Songmei; Ma,Dianfei; Guo,Wenyujie; Long,Hong; Yin,Weiping

doi:10.3892/mmr.2021.12071

MicroRNA‑29‑3p regulates the β‑catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells

Authors:
- Jie Xia
- Songmei Li
- Dianfei Ma
- Wenyujie Guo
- Hong Long
- Weiping Yin
View Affiliations

Affiliations: Department of Pharmacy, Yunnan Hospital of Traditional Chinese Medicine, Kunming, Yunnan 650021, P.R. China, Department of Pediatrics, Kunming Hospital of Traditional Chinese Medicine, Kunming, Yunnan 650011, P.R. China, Department of Pediatrics, Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, P.R. China
Published online on: April 8, 2021 https://doi.org/10.3892/mmr.2021.12071
Article Number: 432
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to analyze the effects and underlying mechanisms of microRNA (miR)‑29‑3p on the proliferation and secretory abilities of prolactinoma cells by targeting insulin‑like growth factor (IGF)‑1/β‑catenin. The relationship between miR‑29a‑3p and the survival of prolactinoma cells was analyzed with the Kaplan‑Meier method in reference to The Cancer Genome Atlas. The expression levels of miR‑29a‑3p and IGF‑1 in MMQ and GH3 cells were detected. A dual‑luciferase reporter gene assay was performed to verify the combination of miR‑29a‑3p and IGF‑1. Cells were transfected with a miR‑29a‑3p mimic and/or IGF‑1 pcDNA3.1 to analyze the effects on the proliferation, apoptosis and secretion of prolactin (PRL) and growth hormone (GH) of prolactinoma cells. The effects on β‑catenin in the cytoplasm and nucleus were investigated by western blot analysis. The results showed that miR‑29a‑3p expression was low in MMQ and GH3 cells. Overexpression miR‑29a‑3p inhibited IGF‑1 mRNA and protein expression. miR‑29a‑3p inhibited cell proliferation and PRL and GH expression, and promoted apoptosis by inhibiting IGF‑1. Increasing the expression of miR‑29a‑3p increased β‑catenin levels in the cytoplasm, whereas IGF‑1 promoted β‑catenin activation and entry into the nucleus, and reversed the inhibitory effects of miR‑29a‑3p on β‑catenin. To conclude, miR‑29a‑3p inhibited the proliferation and secretory abilities of prolactinoma cells by inhibiting nuclear translocation of β‑catenin via a molecular mechanism that is inseparable from IGF‑1.

View Figures

View References

1	Glezer A and Bronstein MD: Prolactinomas. Endocrinol Metab Clin North Am. 44:71–78. 2015. View Article : Google Scholar : PubMed/NCBI
2	Vroonen L, Daly AF and Beckers A: Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 109:20–27. 2019. View Article : Google Scholar : PubMed/NCBI
3	Blanco AM: Hypothalamic- and pituitary-derived growth and reproductive hormones and the control of energy balance in fish. Gen Comp Endocrinol. 287:1133222020. View Article : Google Scholar : PubMed/NCBI
4	Silveira MA, Zampieri TT, Furigo IC, Abdulkader F, Donato J Jr and Frazão R: Acute effects of somatomammotropin hormones on neuronal components of the hypothalamic-pituitary-gonadal axis. Brain Res. 1714:210–217. 2019. View Article : Google Scholar : PubMed/NCBI
5	Kubo T, Furujo M, Mori S, Imai K, Ueda Y, Tsukahara K, Morita H, Ogura K, Fukuhara S, Shimizu J, et al: An infant case of macroprolactinemia with transient idiopathic central precocious puberty. Endocr J. 54:825–828. 2007. View Article : Google Scholar : PubMed/NCBI
6	Tirosh A and Shimon I: Current approach to treatments for prolactinomas. Minerva Endocrinol. 41:316–323. 2016.PubMed/NCBI
7	Faltermeier CM, Magill ST, Blevins LS Jr and Aghi MK: Molecular biology of pituitary adenomas. Neurosurg Clin N Am. 30:391–400. 2019. View Article : Google Scholar : PubMed/NCBI
8	Donoho DA and Laws ER Jr: The role of surgery in the management of prolactinomas. Neurosurg Clin N Am. 30:509–514. 2019. View Article : Google Scholar : PubMed/NCBI
9	Chen T, Zheng F, Tao J, Tan S, Zeng L, Peng X and Wu B: Insulin-like growth factor-1 contributes to mucosal repair by β-arrestin2-mediated extracellular signal-related kinase signaling in experimental colitis. Am J Pathol. 185:2441–2453. 2015. View Article : Google Scholar : PubMed/NCBI
10	Yoneyama Y, Lanzerstorfer P, Niwa H, Umehara T, Shibano T, Yokoyama S, Chida K, Weghuber J, Hakuno F and Takahashi SI: IRS-1 acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling. Elife. 7:e328932018. View Article : Google Scholar : PubMed/NCBI
11	Lyons A, Coleman M, Riis S, Favre C, O'Flanagan CH, Zhdanov AV, Papkovsky DB, Hursting SD and O'Connor R: Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J Biol Chem. 292:16983–16998. 2017. View Article : Google Scholar : PubMed/NCBI
12	Chen KC, Chen PH, Ho KH, Shih CM, Chou CM, Cheng CH and Lee CC: IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PLoS One. 14:e02259132019. View Article : Google Scholar : PubMed/NCBI
13	Cónsole GM, Hereñú CB, Camihort GA, Luna GC, Ferese C and Goya RG: Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas. Cells Tissues Organs. 190:20–26. 2009. View Article : Google Scholar
14	Castillo AI and Aranda A: Differential regulation of pituitary-specific gene expression by insulin-like growth factor 1 in rat pituitary GH4C1 and GH3 cells. Endocrinology. 138:5442–5451. 1997. View Article : Google Scholar : PubMed/NCBI
15	Simonson B and Das S: MicroRNA therapeutics: The next magic bullet? Mini Rev Med Chem. 15:467–474. 2015. View Article : Google Scholar : PubMed/NCBI
16	Hu B, Mao Z, Du Q, Jiang X, Wang Z, Xiao Z, Zhu D, Wang X, Zhu Y and Wang H: miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma. Brain Res Bull. 149:21–31. 2019. View Article : Google Scholar : PubMed/NCBI
17	Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H and Zhu Y: Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1. J Endocrinol Invest. 42:639–652. 2019. View Article : Google Scholar : PubMed/NCBI
18	Xiao Z, Wang Z, Hu B, Mao Z, Zhu D, Feng Y and Zhu Y: MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas. Biochem Biophys Res Commun. 520:79–85. 2019. View Article : Google Scholar : PubMed/NCBI
19	Zhao X, Hou Y, Tuo Z and Wei F: Application values of miR-194 and miR-29 in the diagnosis and prognosis of gastric cancer. Exp Ther Med. 15:4179–4184. 2018.PubMed/NCBI
20	Xu W, Li Z, Zhu X, Xu R and Xu Y: miR-29 family inhibits resistance to methotrexate and promotes cell apoptosis by targeting COL3A1 and MCL1 in osteosarcoma. Med Sci Monit. 24:8812–8821. 2018. View Article : Google Scholar : PubMed/NCBI
21	Gao G, Liang X and Ma W: Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis. Artif Cells Nanomed Biotechnol. 47:3839–3846. 2019. View Article : Google Scholar : PubMed/NCBI
22	Habibi P, Alihemmatti A, Alipour M, Nourazar A, Yousefi H, Andalib S and Ahmadiasl N: Effects of exercise on miR-29 and IGF-1 expression and lipid profile in the heart of ovariectomized rat. Acta Endocrinol (Buchar). 12:130–136. 2016. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Tang H, Zhu D, Zhang G, Luo X and Xie W: AFAP1-AS1 promotes proliferation of pituitary adenoma cells through miR-103a-3p to activate PI3K/AKT signaling pathway. World Neurosurg. 130:e888–e898. 2019. View Article : Google Scholar
25	Molitch ME: Diagnosis and treatment of pituitary adenomas: A review. JAMA. 317:516–524. 2017. View Article : Google Scholar : PubMed/NCBI
26	Lamberts SW, de Quijada M and Klijn JG: The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest. 3:343–347. 1980. View Article : Google Scholar : PubMed/NCBI
27	Watanabe D, Yagasaki H, Kojika S, Ogiwara M, Kinouchi H, Nakane T and Inukai T: GH/PRL-secreting pituitary macroadenoma associated with GNAS p.Gln227Leu mutation: Pediatric case report and review. Endocr J. 66:403–408. 2019. View Article : Google Scholar : PubMed/NCBI
28	Console GM, Herenu CB, Camihort GA, Luna GC, Bracamonte MI, Morel GR and Goya RG: Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas. Mol Cancer. 7:132008. View Article : Google Scholar : PubMed/NCBI
29	Gupta P, Rai A, Mukherjee KK, Sachdeva N, Radotra BD, Punia RPS, Vashista RK, Hota D, Srinivasan A, Dhandapani S, et al: Imatinib inhibits GH secretion from somatotropinomas. Front Endocrinol (Lausanne). 9:4532018. View Article : Google Scholar : PubMed/NCBI
30	Kempf J, Schmitz A, Meier A, Delfs N, Mueller B, Fandino J, Schuetz P and Berkmann S: Adenoma size and postoperative IGF-1 levels predict surgical outcomes in acromegaly patients: Results of the Swiss pituitary registry (SwissPit). Swiss Med Wkly. 148:w146532018.PubMed/NCBI
31	O'Neill BT, Lee KY, Klaus K, Softic S, Krumpoch MT, Fentz J, Stanford KI, Robinson MM, Cai W, Kleinridders A, et al: Insulin and IGF-1 receptors regulate FoxO-mediated signaling in muscle proteostasis. J Clin Invest. 126:3433–3446. 2016. View Article : Google Scholar
32	Cui X, Li M, He Z, Hu L, Liu J, Yan J and Hua L: MiR-302b-5p enhances the neuroprotective effect of IGF-1 in methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease by regulating inducible nitric-oxide synthase. Cell Biochem Funct. 38:1025–1035. 2020. View Article : Google Scholar : PubMed/NCBI
33	Wang T, Liu Y, Lv M, Xing Q, Zhang Z, He X, Xu Y, Wei Z and Cao Y: miR-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting IGF-1. Gene. 683:87–100. 2019. View Article : Google Scholar : PubMed/NCBI
34	Zhou Y, Li S, Li J, Wang D and Li Q: Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer. Cell Physiol Biochem. 42:1431–1446. 2017. View Article : Google Scholar : PubMed/NCBI
35	Liu Y, Hu Q, Ao J, Li H and Li M: Role of miR-92a-3p/PTEN axis in regulation of pancreatic cancer cell proliferation and metastasis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 45:280–289. 2020.(In English, Chinese). PubMed/NCBI
36	Wang Y, Zhao R, Liu W, Wang Z, Rong J, Long X, Liu Z, Ge J and Shi B: Exosomal circHIPK3 released from hypoxia-pretreated cardiomyocytes regulates oxidative damage in cardiac microvascular endothelial cells via the miR-29a/IGF-1 pathway. Oxid Med Cell Longev. 2019:79546572019. View Article : Google Scholar : PubMed/NCBI
37	Shastri AA, Saleh A, Savage JE, DeAngelis T, Camphausen K and Simone NL: Dietary alterations modulate the microRNA 29/30 and IGF-1/AKT signaling axis in breast cancer liver metastasis. Nutr Metab (Lond). 17:232020. View Article : Google Scholar : PubMed/NCBI
38	Li Z, Jiang R, Yue Q and Peng H: MicroRNA-29 regulates myocardial microvascular endothelial cells proliferation and migration in association with IGF1 in type 2 diabetes. Biochem Biophys Res Commun. 487:15–21. 2017. View Article : Google Scholar : PubMed/NCBI
39	Cao L, Gao H, Li P, Gui S and Zhang Y: The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells. Tumour Biol. 35:5121–5127. 2014. View Article : Google Scholar : PubMed/NCBI
40	Chauvet N, Romanò N, Meunier AC, Galibert E, Fontanaud P, Mathieu MN, Osterstock G, Osterstock P, Baccino E, Rigau V, et al: Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J Neuroendocrinol. 28:123522016. View Article : Google Scholar : PubMed/NCBI
41	Wang C, Tan C, Wen Y, Zhang D, Li G, Chang L, Su J and Wang X: FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway. Cell Death Dis. 10:4992019. View Article : Google Scholar : PubMed/NCBI
42	Lei C, Jing G, Jichao W, Xiaohui L, Fang Q, Hua G, Yazhou M and Zhang Y: MiR-137′s tumor suppression on prolactinomas by targeting MITF and modulating Wnt signaling pathway. J Clin Endocrinol Metab. 104:6391–6402. 2019. View Article : Google Scholar : PubMed/NCBI